Fulcrum Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
a)
None.
b)
Director and Officer Trading Plans and Arrangements.
On December 26, 2025, Katina Dorton, a member of our board of directors, adopted a trading plan for the potential exercise of vested stock options and the associated sale of up to 140,000 shares of our common stock. The trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and is expected to remain in effect until December 15, 2026.
On December 29, 2025, Alan Ezekowitz, a member of our board of directors, adopteda trading plan for the potential exercise of vested stock options and the associated sale of up to 124,713 shares of our common stock. The trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and is expected to remain in effect until December 31, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.